Journal: Drug Invention Today

Article Id: JPRS-Pcol-00004473
Title: Correction of endothelial dysfunction by arginase type II inhibitors and tadalafil in rats
Category: Pharmacology
Section: Research Article
  • Abstract
  • Audio Abstract
  • Authors
  • Pdf File
  • Citation
  • My Reference
  • Methodology
  • Abstract

    Background: Endothelial dysfunction (ED) is one of the most cardiovascular disease pathogenesis leaders. This fact discloses a large number of potential molecular targets for novel pharmacological drugs. Among these targets, enzymes arginase type II and phosphodiesterase type 5 can be distinguished. Materials and Methods: The study included 120 male Wistar rats weighting 250–300 g, which were randomly divided into 12 equal groups. The screening was carried out among compounds with laboratory codes C239–0844, L207–0208, L207–0210, L207–0322, L207–0404, L207–0525, and L327–0346. N-nitro- L-arginine methyl ether (L-NAME)-induced ED was modeled by daily intraperitoneal injection of L-NAME at a dose of 25 mg/kg to male rats for 7 days. The degree of coefficient of ED (CED) was determined on the 8th day from the beginning of the experiment. In parallel, a test was performed for adrenoreactivity and myocardial reserve exhaustion, as well as an assessment of the values of biochemical markers (total nitric oxide [NO] and endothelial NO synthase [eNOS] expression). Results and Discussion: Compounds L207–0525 and L327–0346 at a dose of 1 mg/kg showed the highest activity and were showing the values of CED 1.5 ± 0.3 and 1.9 ± 0.4 c.u., respectively, whereas in the control, it was 5.4 ± 0.4 c.u. At the same time, studied compounds showed cardioprotective effect, what expressed in adrenoreactivity decrease and myocardial reserve exhaustion, as well as a lowering of NO metabolites (NOx) values and expression of eNOS. The combined use of tadalafil and arginase II inhibitors increased the endothelioprotective effect but did not enhance the cardioprotective effect. Conclusion: The study proved the possibility of arginase inhibitors using to prevent the ED development. Among arginase II inhibitors, the most promising compounds are L207–0525 and L327–0346.

  • Abstract Audio

    No Audio file found

  • About the authors and Affiliations

    Author(s) Name:

    Ivan C. Koklin*, Mikhail V. Pokrovskiy, Lyudmila М. Danilenko, Konstantin S. Trunov, Anton P. Danilenko, Vladislav O. Soldatov, Natalia N. Bystrova, Natalia N. Bunatyan

    Affiliation(s) Name:

    Department of Pharmacology and Clinical Pharmacology, Medical Institute, Belgorod State University, 85, Pobedy St., Belgorod 308015, Russia

    *Corresponding author: Ivan C. Koklin, Department of Pharmacology and Clinical Pharmacology, Medical Institute, Belgorod State National Research University, 85, Pobedy St., Belgorod 308015, Russia.

  • View Article File in pdf format.

    Article File
  • View Article Citation Here.

    0 View More
  • How to Cite my Article.

    Author:

    Ivan C. Koklin*, Mikhail V. Pokrovskiy, Lyudmila М. Danilenko, Konstantin S. Trunov, Anton P. Danilenko, Vladislav O. Soldatov, Natalia N. Bystrova, Natalia N. Bunatyan

    Title:Correction of endothelial dysfunction by arginase type II inhibitors and tadalafil in rats
    Journal:Drug Invention Today
    Vol(issue):12 (November )
    Year:2019
    Page No: (2731-2735)
  • Experimental Methods Keywords

    Methodology:Endothelial dysfunction
    Research Materials:Arginase II inhibitors,Tadalafil

Keywords

Arginase II inhibitors Endothelial dysfunction N-nitro-L-arginine methyl ether Tadalafil

Our Services

Most Downloaded List